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Abstract
Background: The G994T polymorphism in platelet-activating factor acetylhydrolase (PAF-AH) gene is associated with
the risk of polycystic ovary syndrome (PCOS). The aim of this study was to investigate the relationship between
R92H and A379V variants of the PAF-AH gene and the risk of PCOS and to evaluate the effects of the genotypes on
PAF-AH activities and clinical, metabolic and oxidative stress indexes in Chinese women.
Methods: A total of 862 patients with PCOS based on the Rotterdam consensus criteria and 750 control women from a
population of Chinese Han nationality in the Chengdu area were studied from 2006–2015. PAF-AH genotypes were
determined by PCR and restriction fragment length polymorphism analysis. Plasma PAF-AH, high-density lipoprotein
(HDL)-associated PAF-AH (H-PAF-AH) and apolipoprotein (apo) B-containing lipoprotein-associated PAF-AH (apoB-PAF-AH)
activities were measured using the trichloroacetic acid precipitation procedure with PAF C-16 as a substrate. Circulating
markers of oxidative stress, including serum total oxidant status, total antioxidant capacity, oxidative stress index and
malondialdehyde levels, and clinical and metabolic parameters were also analyzed.
Results: No significant differences were observed in the frequencies of R92H and A379V genotypes and alleles of
the PAF-AH gene between PCOS and control groups (P > 0.05). Compared with patients with the 92RR genotype,
patients with H allele of R92H (RH + HH genotype) had significantly higher plasma PAF-AH and apoB-PAF-AH
activities (P < 0.05) and tended to exhibit increased H-PAF-AH activity (P = 0.063) after adjusted for age and BMI.
However, when serum LDL-C, HDL-C, TG and HOMA index were added as covariates, the comparisons no longer
remained statistical significance (P > 0.05). There were no significant differences in clinical, hormonal, metabolic
and circulating oxidative stress parameters and the frequencies of PAF-AH G449T genotype according to PAF-AH
R92H or A379V genotyping in patients with PCOS and control women.
Conclusions: There were no significant associations between R92H and A379V variants of PAF-AH gene and risk of
PCOS in Chinese women. The increased plasma PAF-AH and apoB-PAF-AH activities in patients with H allele of R92H
are related to the R92→ H variation, changes in plasma lipoprotein levels, insulin resistance, aging, and gaining weight
and thus may be involved in the pathogenesis of PCOS and the increased risks of future cardiovascular diseases.
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Background
Polycystic ovary syndrome (PCOS) is a heterogeneous
female endocrine metabolic disorder affecting 5–15% of
reproductive-age women [1, 2]. In addition to reproduct-
ive disorders, PCOS is often associated with long-term
health risks, including insulin resistance, obesity, dyslip-
idemia, increased oxidative stress, chronic low-grade
inflammation, endothelial dysfunction and vascular
injury, elevated risks of metabolic syndrome, type 2
diabetes, and future cardiovascular diseases [2–9]. The
etiology of PCOS remains obscure, but studies have
suggested that PCOS has a complex, multifactorial
etiology resulting from the interactions between genetic,
environmental and intrauterine factors [10–12].
Plasma platelet-activating factor (PAF) acetylhydrolase
(PAF-AH), also known as lipoprotein-associated phospho-
lipase A2 (Lp-PLA2), is mainly bound to apolipoprotein
(apo) B-containing lipoproteins, particularly low-density
lipoprotein (LDL), and a small portion is also associated
with high-density lipoprotein (HDL) [13, 14]. The ab-
normalities of plasma PAF-AH activity, mass and/or
distribution in lipoproteins are associated with athero-
sclerosis and inflammatory diseases [14–16]. Decreased
HDL-associated PAF-AH (H-PAF-AH) activities, in-
creased apoB-containing lipoprotein-associated PAF-AH
(apoB-PAF-AH) activities and/or the ratio of apoB-PAF-
AH to total or H-PAF-AH activity are associated with
cardiovascular diseases [14], type 2 diabetes [17], gesta-
tional diabetes mellitus [13], pre-eclampsia [18], and poly-
cystic ovary syndrome [19, 20] and might be markers for
chronic inflammation in these patients.
Several single-nucleotide polymorphisms (SNPs) in the
exon region of the PAF-AH gene influence its activity or
concentration. The V279F (G994T) SNP in exon 9 com-
pletely abolishes enzymatic activity in 279 FF homozy-
gotes and results in a 50% decrease of catalytic activity
in heterozygotes [19, 21]. The V allele of the A379V SNP
in exon 11 results in a two-fold decrease in the affinity
of PAF-AH for PAF [22]. The H allele of the R92H SNP
in exon 4 is associated with a higher PAF-AH mass [16].
Several studies reported that the PAF-AH R92H and
A379V variants were associated with increased risk of
coronary heart disease (CHD), but the results were
inconsistent [14, 15, 23, 24]. However, the evidence avail-
able to date strongly suggests that PAF-AH G994→ T
mutation is associated with increased risk of cardiovascu-
lar diseases in Japanese and Chinese cohorts [14, 24].
Previously Fan et al. demonstrated that the T allele of
the G994T SNP in PAF-AH gene was one of the genetic
determinants for PCOS in Chinese Han women [19].
Plasma PAF-AH hydrolyzes and inactivates PAF and
PAF-like oxidized phospholipids, and is associated with
circulating oxidative stress and inflammation status [14,
24]. However, to date, little information is available
regarding the possible connection between the PAF-AH
gene A379V and R92H SNPs and PCOS or oxidative
stress. In the present study, we investigated the relation-
ship between R92H and A379V variants of PAF-AH gene
and the risk of PCOS and evaluated the effects of the
genotypes on PAF-AH activities and clinical, metabolic
and oxidative stress indexes in Chinese women.
Methods
Study subjects
This is a case-control study, which consists of 862 cases
and 755 controls. The frequencies of PAF-AH genotype
and allele are main variables. The sample sizes in the
present study are reasonable and practicable according
to a report by B-Rao [25].
Women with or without PCOS aged 17–40 years
were recruited from 2006–2015 from the Outpatient
Clinic of Reproductive Endocrinology, West China
Second University Hospital.
Each woman with PCOS met diagnostic criteria for
PCOS based on the revised 2003 Rotterdam ESHRE/
ASRM consensus criteria [26]. Oligo- or anovulation
(OA) was assessed as oligomenorrhea (i.e., fewer than
eight cycles per year). Biochemical or clinical hyperan-
drogenism (HA) was assessed by total testosterone (TT)
levels above the 95th percentile of the levels (2.60 nmol/l)
detected in a group of normal menstruating women with
normal cycles, hirsutism with a modified Ferriman–
Gallwey (F-G) score of more than 6 and/or clinical
presence of obvious acne [4, 27, 28]. Polycystic ovaries
(PCOs) were confirmed if there were 12 or more folli-
cles in each ovary measuring 2–9 mm in diameter and/
or increased ovarian volume (>10 mL) by ultrasonic
examination. The diagnosis of PCOS was based on a
patient having two of these three findings for women
aged 20–40 years or having all three findings for
women aged < 20 years [2], with exclusion of other eti-
ologies, such as androgen-secreting tumors, congenital
adrenal hyperplasias, and Cushing syndrome. All of the
control women had regular menstrual cycles (between
21 and 35 days), exhibited normal circulating androgen
levels, the absence of hirsutism or obvious acne on
physical examination, and normal ovarian morphology
as determined by ultrasound.
None of the subjects had clinically evident chronic or
acute diseases, such as infection, tumors, cardiovascular
disease, thyroid dysfunction, endometriosis, hyperprolac-
tinemia, hypogonadotropic hypogonadism or premature
ovarian failure.
For association studies between PAF-AH genotypes
and hormonal, metabolic and oxidative stress parame-
ters, the subjects were excluded if they met one of the
following criteria: [i] taking medication known to affect
the metabolism of carbohydrates, lipids, or hormones
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within 3 months before the study; [ii] pregnant or in the
luteal phase; and [iii] smokers.
Clinical and anthropometrical variables, including
waist circumference, hip circumference, waist-to-hip ra-
tio, body mass index (BMI, kg/m2), systolic and diastolic
blood pressure (SBP and DBP), and the degree of hirsut-
ism and acne were measured or assessed in all subjects.
Ultrasound ovarian volume was also assessed using the
formula [29]: 0.523 × length × width × thickness.
Blood samples were obtained in the morning after
overnight fasting, placed on ice immediately and centri-
fuged at 1500 g for 15 min at 4 °C within 2 h. Plasma or
serum aliquots were stored at −80 °C and blood cells
were stored at 4 °C.
Genotype analysis
Genomic DNA was isolated from peripheral blood leu-
kocytes of subjects [28, 30]. The PAF-AH R92H and
A379V genotypes were determined by PCR amplification
and restriction analysis. For the R92H genotype, a 200-
bp fragment was amplified using the following primers
[31]: forward, 5’-ATGCAAAATAGCTGCTGGAA-3’
and reverse 5’-AATGTTGCCCATAAGCCAGT-3’. For
the A379V genotype, a 99-bp fragment was amplified using
the following primers [22]: forward, 5’-GGGAGACATAGA
TTCAACTG-3’ and reverse 5’-GGTCATGAAAAAAATA
GTTT-3’. R92H and A379V PCR products were digested
with BclI or PstI (MBI Fermentas, Vilnius, Lithuania),
respectively, analyzed by electrophoresis on a 3.5% agarose
gel and visualized by staining with Genecolour fluorescent
dye. For the purpose of genotyping quality control, greater
than 30% of DNA samples were genotyped again by the
different operator.
Measurements of plasma PAF-AH, H-PAF-AH and
apoB-PAF-AH activities
HDL fractions were obtained by precipitating apoB-
containing lipoproteins using 13% polyethylene glycol
(PEG) 6000. The plasma PAF-AH and H-PAF-AH activ-
ities were measured via the trichloroacetic acid precipi-
tation procedure as previously described [19, 32]. The
intra- and inter-assay coefficients of variation for all
measurements were less than 3% and 5%, respectively.
The apoB-PAF-AH activity was obtained by subtracting
the H-PAF-AH activity from plasma PAF-AH activity.
Analysis of oxidative stress, hormonal and metabolic
markers
Serum follicle stimulating hormone (FSH), luteinizing
hormone (LH), TT, estradiol (E2), total cholesterol (TC),
triglyceride (TG), HDL-cholesterol (HDL-C), LDL-
cholesterol (LDL-C), apoA1, apoB, total oxidant status
(TOS), total antioxidant capacity (T-AOC) and malon-
dialdehyde (MDA) levels, plasma insulin and glucose
concentrations as well as homeostatic model assessment
of insulin resistance (HOMA index) and oxidative stress
index (OSI) were measured or assessed as described be-
fore [4, 33, 34]. The intra- and inter-assay coefficients of
variation for all measurements were less than 5% and
10%, respectively.
Statistical analysis
Data were presented as the mean ± standard deviation
(SD). Differences in variables were evaluated by the inde-
pendent sample t-test between PCOS and control subjects.
Variables with asymmetric distribution were evaluated by
nonparametric tests (Mann-Whitney U test). X2 analysis
was used to test deviations of genotype distribution from
Hardy-Weinberg equilibrium and to determine allele or
genotype frequencies between patients and controls.
Analysis of covariance was used to estimate the dif-
ferences in metabolic and oxidative stress parameters
and PAF-AH activities between two groups after
correction for differences in covariates such as age,
BMI and serum lipid levels. Pearson correlation was
performed to define the correlations between PAF-AH
activities and the other parameters in patients with
PCOS. A P-value < 0.05 was considered to be statisti-
cally significant. All statistical analyses were performed
using Statistical Program for Social Sciences (SPSS)
13.0 for Windows (Chicago, IL, USA).
Results
Clinical and biochemical characteristics of the study
population
In accordance with the revised 2003 Rotterdam criteria,
there were 358 cases (41.5%) with OA +HA+ PCO, 276
cases (32%) with OA + PCO, 183 cases (21.2%) with
OA + HA, and 45 cases (5.2%) with HA+ PCO in the
PCOS group.
As shown in Table 1, BMI, waist circumference,
waist-to-hip ratio, F-G score, DBP, and average ovar-
ian volume were significantly increased, and age was
significantly lower in the PCOS group compared with
the control group.
TT and LH levels, the ratio of LH to FSH, fasting insu-
lin concentration, HOMA index, TG, TC, LDL-C, apoB
and MDA levels, TOS, T-AOC, OSI, the ratio of apoB-
PAF-AH to H-PAF-AH and the frequency of the T allele
carriers (GT + TT) of PAF-AH G994T were significantly
increased and FSH and HDL-C levels and H-PAF-AH
activities were significantly reduced in the PCOS group
compared with the control group after adjusted for age
and BMI (Table 2). However, when serum LDL-C, HDL-
C, TG and HOMA index were added as covariates, the
comparisons of plasma PAF-AH, apoB-PAF-AH and
H-PAF-AH activities as well as the ratio of apoB-PAF-
AH to H-PAF-AH were statistically significant (P < 0.05).
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Distribution of PAF-AH R92H and A379V genotypes and
alleles
Genotypic distributions of PAF-AH R92H and A379V
were in Hardy-Weinberg equilibrium in the PCOS and
control groups. No significant differences were
observed in the frequencies of PAF-AH R92H and
A379V genotypes and alleles between PCOS and
control groups (P > 0.05, Table 3).
Effects of PAF-AH R92H and A379V genetic variants on
clinical, hormonal, metabolic and oxidative stress
parameters and PAF-AH activities
We further analyzed effects of PAF-AH R92H and
A379V genetic variants on oxidative stress parameters
and PAF-AH activities as well as clinical, hormonal,
metabolic parameters in PCOS patients and control
women. Because the sample sizes of the 92HH or 379VV
homozygotes were too small, we combined them into
heterozygous subgroups.
As shown in Table 4, compared with patients with 92
RR genotype, patients with H allele of R92H (RH +HH
genotype) had significantly higher plasma PAF-AH (P =
0.034) and apoB-PAF-AH activities (P = 0.045) and tended
to exhibit increased H-PAF-AH activity (P = 0.063) after
adjusted for age and BMI. Similar alterations were also ob-
served in the control group, but the values did not reach
statistical significance (P > 0.05). In addition, when serum
LDL-C, HDL-C, TG and HOMA index were added as
covariates, plasma PAF-AH, apoB-PAF-AH and H-PAF-
AH activities no longer remained statistical signifi-
cance between patients with 92 RR genotype and
patients with H allele (P = 0.054, 0.243 and 0.183,
respectively). No significant differences in oxidative
stress indexes and the frequencies of PAF-AH G449T
genotype (Table 4) and clinical, hormonal, metabolic
parameters (data not shown) according to PAF-AH
R92H genotyping were detected in PCOS patients and
control women (P > 0.05).
No significant differences in oxidative stress indexes,
the frequencies of PAF-AH G449T genotype and PAF-
AH activities (Table 5) as well as other clinical, hormo-
nal, and metabolic parameters (data not shown) accord-
ing to PAF-AH A379V genotypes were detected in PCOS
patients and control women (P > 0.05).
Discussion
In the present study, we show that PAF-AH R92H and
A379V genetic polymorphisms are not associated with
the risk of PCOS in Chinese women. However, we found
that plasma PAF-AH and apoB-PAF-AH activities in pa-
tients carrying the minor allele of R92H polymorphism
of PAF-AH gene are increased compared with those
homozygous for the wild-type allele, suggesting that the
R92H variant may be associated with increased plasma
and lipoprotein-associated PAF-AH activities in these
patients. In addition, our results revealing no significant
differences in TOS, OSI and MDA levels according to
R92H or A379V genotypes in PCOS and control groups
suggests that these genetic variants that modestly or
minimally impact enzymatic activity are unlikely to
significantly affect circulating oxidative stress levels.
Plasma PAF-AH specifically hydrolyzes and inactivates
PAF and PAF-like oxidized phospholipids that are potent
pro-inflammatory mediators and thus plays an anti-
inflammatory role [14, 24]. Genetic studies in humans
harboring an inactivating mutation (PAF-AH G994→ T
mutation) indicate that loss of PAF-AH activity is a risk
factor for inflammatory and cardiovascular diseases in
Japanese cohorts [14, 24]. Consistently, overexpression
of PAF-AH has anti-inflammatory and anti-atherogenic
properties in animal models [14, 24, 35]. However,
several clinical studies have demonstrated that plasma
PAF-AH activity and mass are strongly associated with
atherogenic lipids and risk of cardiovascular disease
[14, 16, 24, 36]. The hydrolysis products of this enzyme,
lysophosphatidylcholine (lyso-PC) and oxidatively modi-
fied nonesterified fatty acids, promote the pathogenesis of
atherosclerosis [14, 24, 35]. Thus, controversy remains
regarding whether plasma PAF-AH exerts a pro- or anti-
inflammatory action. Given that H-PAF-AH, one of anti-
oxidant enzymes of HDL, plays anti-inflammatory role
[14, 19] and apoB-PAF-AH is associated with inflamma-
tion [13, 14, 24], it has recently been suggested that the
relative distribution of the enzyme between apoB-
containing lipoproteins and HDL determines its pro- or
anti-inflammatory actions. Previous studies indicated that
H-PAF-AH activity was decreased and the ratio of
LDL-associated PAF-AH to H-PAF-AH activities and
MDA levels were increased in women with PCOS, and
the PAF-AH G994→ T gene mutation is a risk factor for
PCOS [19, 20, 32]. Consistent with previous studies, this
study further determined that patients with PCOS had
significantly higher TOS, OSI, and the ratio of apoB-
PAF-AH to H-PAF-AH activities compared with the
Table 1 Clinical characteristics in PCOS patients and control
women
Controls (n = 750) PCOS (n = 862) P
Age (years) 28.16 ± 4.15 24.68 ± 3.90 0.000
BMI (kg/m2) 21.16 ± 2.95 22.79 ± 4.04 0.000
Waist circumference (cm) 73.60 ± 8.22 78.68 ± 11.12 0.000
Waist-to-hip ratio 0.82 ± 0.06 0.85 ± 0.07 0.000
F-G score 0.22 ± 0.72 1.68 ± 2.03 0.000
SBP (mmHg) 113.24 ± 11.46 114.20 ± 10.57 0.084
DBP (mmHg) 73.92 ± 8.97 75.62 ± 8.90 0.000
Ovarian volume (ml) 7.52 ± 2.87 9.89 ± 4.10 0.000
Values are presented as the mean ± SD
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control women, suggesting that increased circulating
absolute (TOS) and relative (OSI) oxidative stress levels
and chronic inflammation existed in these patients.
Several studies have demonstrated that the PAF-AH
92R→H genetic variant was associated with an in-
creased PAF-AH mass [15, 16, 23] and was a risk factor
of CHD [23, 37]. However, in meta-analyses, the PAF-
AH R92H genetic polymorphism was not significantly
associated with the risk of CHD [15]. In the present
study, we showed that this genetic polymorphism was
not associated with the risk of PCOS in Chinese women.
However, the PAF-AH 92R→H variant was significantly
associated with increased plasma and lipoprotein-
associated PAF-AH activities in PCOS patients after
adjusted for age and BMI, but when LDL-C, HDL-C,
TG, and HOMA-IR were added as covariates, the statis-
tical differences were no longer maintained. Grallert et
al [15] indicated that PAF-AH activity was strongly asso-
ciated with genetic variants involved in lipid metabolism.
A previous study also demonstrated that the ratio of
L-PAF-AH to H-PAF-AH activities was positively corre-
lated with LDL-C, TG, HOMA-IR, fasting plasma insulin
and glucose concentrations, and negatively correlated
with HDL-C levels in patients with PCOS [20]. Similarly,
Table 2 Hormonal, metabolic and oxidative stress parameters and PAF-AH activities in PCOS patients and control women
Controls (n = 501) PCOS (n = 565) P Pa
Age (years) 27.93 ± 4.20 24.69 ± 3.90 0.000
BMI (kg/m2) 21.07 ± 2.89 23.08 ± 4.24 0.000
Hormonal levels
E2 (pmol/L) 331.82 ± 350.14 286.60 ± 272.76 0.027 0.587
TT (nmol/L) 1.53 ± 0.56 2.43 ± 0.76 0.000 0.000
LH (IU/L) 8.63 ± 10.94 13.93 ± 10.97 0.000 0.000
FSH (IU/L) 6.67 ± 2.97 5.99 ± 2.25 0.000 0.018
LH/FSH 1.30 ± 1.31 2.36 ± 1.27 0.000 0.000
Metabolic profile and oxidative stress parameters
Fasting Ins (pmol/L) 66.12 ± 35.49 105.43 ± 72.16 0.000 0.000
Fasting Glu (mmol/L) 5.30 ± 0.74 5.37 ± 0.78 0.108 0.473
HOMA-IR 2.32 ± 1.85 3.77 ± 3.13 0.000 0.001
TG (mmol/L) 1.04 ± 0.90 1.43 ± 1.37 0.000 0.000
TC (mmol/L) 4.24 ± 0.70 4.41 ± 0.81 0.000 0.000
HDL-C (mmol/L) 1.51 ± 0.32 1.38 ± 0.35 0.000 0.008
LDL-C (mmol/L) 2.34 ± 0.61 2.55 ± 0.76 0.000 0.000
ApoA1 (g/L) 1.45 ± 0.21 1.41 ± 0.21 0.005 0.772
ApoB (g/L) 0.75 ± 0.17 0.82 ± 0.20 0.000 0.000
TOS (nmol H2O2 Equiv./mL) 11.20 ± 5.31 14.96 ± 10.81 0.000 0.000
T-AOC (U/ml/min) 14.54 ± 2.67 15.81 ± 3.07 0.000 0.000
OSI 0.80 ± 0.40 1.00 ± 0.80 0.000 0.000
MDA (nmol/ml) 3.65 ± 1.08 4.36 ± 1.13 0.000 0.000
PAF-AH activities and frequencies of PAF-AH G449T genotypea
Plasma PAF-AH (nmol/min/ml) 48.34 ± 10.81 47.44 ± 12.94 0.371 0.741
H-PAF-AH (nmol/min/ml) 5.11 ± 1.48 4.66 ± 1.91 0.002 0.038
ApoB-PAF-AH (nmol/min/ml) 43.25 ± 9.96 42.77 ± 11.89 0.625 0.976
ApoB-PAF-AH/H-PAF-AH 8.88 ± 2.47 10.04 ± 3.89 0.000 0.000
PAF-AH G449T, n (%)
GG 255 (92.7%) 243 (86.5%)
GT + TT 20 + 0 (7.3%) 34 + 4 (13.5%) 0.020
Values are presented as the mean ± SD
ApoA1 apolipoprotein A1, apoB apolipoprotein B, TOS total oxidant status, T-AOC total antioxidant capacity, OSI oxidative stress index, PAF-AH platelet activating
factor acetylhydrolase, H-PAF-AH HDL-associated PAF-AH, ApoB-PAF-AH apolipoprotein B-containing lipoprotein-associated PAF-AH
Pa All comparisons of parameters were corrected for differences in age and BMI between the two groups
aControls (n = 275), PCOS (n = 281)
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the present study indicated that plasma PAF-AH and
apoB-PAF-AH activities were positively correlated with
LDL-C, apoB, TC, TG, age, SBP, waist circumference,
waist-to-hip ratio, and HOMA-IR (P < 0.05) and nega-
tively correlated with HDL-C levels (P < 0.05) in the
patients according to the correlation analysis (data not
shown). In addition, evidence suggests that PAF, oxidized
LDL, and oxidized phospholipids upregulate expression
of PAF-AH in vivo [24]. These results suggest that
multiple factors including the 92R→H variant, changes
in plasma lipoprotein levels, increased oxidative stress
or/and chronic inflammation, insulin resistance, aging,
and gaining weight may contribute to increased plasma
and lipoprotein-associated PAF-AH activities according
to PAF-AH R92H genotypes in PCOS patients.
The PAF-AH 379A→V variant results in a two-fold
decrease in the affinity of PAF-AH for its substrates [22],
thus prolonging the pro-inflammatory actions of PAF
and PAF-like oxidized phospholipids in plasma. How-
ever, the effect of this variant on PAF-AH activity or
disease is conflicting. The 379A→V variant is associated
with increased [15, 31, 36] or decreased [38] activity and
increased [38, 39], decreased [40, 41] or no affect [15, 36]
on the risk of cardiovascular diseases. Our study
determined that the A379V SNP was not significantly
associated with the risk of PCOS and PAF-AH activities in
Chinese women.
In particular, the allele frequencies for PAF-AH genetic
variants differ among ethnic groups [14, 24]. For ex-
ample, the G994T SNP is common in Japanese and
Taiwan populations and has been reported in Korean,
Chinese, Turkey populations; however, this SNP is rarely
observed in Europeans [24]. In the present study, the
frequency of the T allele carriers (GT + TT) of PAF-AH
G994T was significantly increased in the PCOS group
compared with the control group (P = 0.02, Table 2).
This may be an important reason why patients with
Table 3 Frequencies of PAF-AH genotype and allele in PCOS
patients compared with control women
Controls (n = 750) PCOS (n = 862) X2 P
Genotype
92 RR 486 (64.8%) 535 (62.1%)
RH 238 (31.7%) 294 (34.1%)
HH 26 (3.5%) 33 (3.8%) 1.302 0.522
379 AA 564 (75.2%) 647 (75.1%)
AV 171 (22.8%) 202 (23.4%)
VV 15 (2.0%) 13 (1.5%) 0.629 0.700
Allele frequency
92 R 0.807 0.791
H 0.193 0.209 1.195 0.274
379 A 0.866 0.868
V 0.134 0.132 0.021 0.884
Data of genotype are presented as number (%) of patients or controls
Table 4 Oxidative stress parameters and PAF-AH activities according to PAF-AH R92H genotype in PCOS patients and control women
Controls PCOS
RR (n = 335) RH + HH (n = 151 + 15) RR (n = 357) RH + HH (n = 186 + 22)
Age (yr) 28.10 ± 4.23 27.58 ± 4.12 24.98 ± 3.29 24.20 ± 3.81a
BMI (kg/m2) 21.14 ± 3.05 20.92 ± 2.53 23.09 ± 4.33 23.07 ± 4.10
Oxidative stress parameters
TOS (nmol H2O2 Equiv./mL) 11.27 ± 5.49 10.99 ± 4.92 15.42 ± 11.83 14.17 ± 8.88
T-AOC (U/ml/min) 14.38 ± 2.58 14.85 ± 2.84 15.84 ± 3.21 15.80 ± 2.83
OSI 0.81 ± 0.42 0.76 ± 0.37 1.02 ± 0.84 0.95 ± 0.72
MDA (nmol/ml) 3.67 ± 1.10 3.61 ± 1.04 4.31 ± 1.25 4.42 ± 1.14
PAF-AH activities and frequencies of PAF-AH G449T genotype*
Plasma PAF-AH (nmol/min/ml) 48.02 ± 11.14 48.90 ± 10.26 46.30 ± 13.32 49.37 ± 12.08a
H-PAF-AH (nmol/min/ml) 5.04 ± 1.41 5.25 ± 1.59 4.51 ± 1.75 4.92 ± 2.14
ApoB-PAF-AH (nmol/min/ml) 42.98 ± 10.31 43.64 ± 9.37 41.79 ± 12.23 44.45 ± 11.14a
ApoB-PAF-AH/H-PAF-AH 8.94 ± 2.60 8.77 ± 2.25 10.15 ± 4.37 9.85 ± 2.95
PAF-AH G449T, n (%)
GG 158 (90.8%) 97 (96.0%) 150 (84.7%) 93 (89.4%)
GT + TT 16 + 0 (9.2%) 4 + 0 (4.0%) 23 + 4 (15.3%) 11 + 0 (10.6%)
Values are presented as the mean ± SD
TOS total oxidant status, T-AOC total antioxidant capacity, OSI oxidative stress index, PAF-AH platelet activating factor acetylhydrolase, H-PAF-AH HDL-associated
PAF-AH, ApoB-PAF-AH apolipoprotein B-containing lipoprotein-associated PAF-AH
Comparisons of oxidative stress parameters and PAF-AH activities were corrected for differences in age and BMI between the two groups
aP < 0.05, compared with RR genotype subgroup in PCOS patient
*Controls: RR (n = 174), RH + HH (n = 88 + 13); PCOS: RR (n = 177), RH + HH (n = 98 + 6)
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PCOS have higher TC, TG and LDL-C levels, but have
relatively lower plasma PAF-AH and apoB-PAF-AH ac-
tivities. Because The G994→ T variation completely
abolishes enzymatic activity in TT homozygotes and re-
sults in a 50% decrease of catalytic activity in heterozy-
gotes [19, 21]. In addition, environmental factors, such
as increased oxidative stress, inflammation status, a
high-fat diet, and lipoprotein levels may also affect PAF-
AH expression or the distribution of this enzyme in lipo-
proteins [16, 19, 20, 24]. Therefore, it is possible that the
relationships between PAF-AH genetic polymorphisms
and PAF-AH activities or diseases may differ among
different populations.
Regarding limitations of the present study, given
the low frequency of homozygosity of minor alleles,
92HH and 379VV, we could not analyze them in the
form of subgroups, and a larger number of subjects
are needed to properly evaluate dose dependent
genotype characteristics. Second, due to insufficient
sample, we did not assess plasma and lipoprotein-
associated PAF-AH activities in some subjects, which
might influence the power of these parameters or
result in the absence of statistical significances. Fur-
ther study to increase the sample size for PAF-AH
activity determination may help improve statistical
power of these parameters between the two different
genotype subgroups.
Conclusion
The present study demonstrates that PAF-AH R92H and
A379V genetic polymorphisms are not associated with the
risk of PCOS and the circulating absolute and relative oxi-
dative stress levels in Chinese women. The increased
plasma PAF-AH and apoB-PAF-AH activities in patients
with H allele of R92H are related to multiple factors in-
cluding the R92→H variation, changes in plasma lipopro-
tein levels, insulin resistance, aging, and gaining weight
and thus might be involved in the pathogenesis of
PCOS and the increased risks of future cardiovascular
diseases in the patients.
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Table 5 Oxidative stress parameters and PAF-AH activities according to PAF-AH A379V genotype in PCOS patients and con-
trol women
Controls PCOS
AA (n = 371) AV + VV (n = 121 + 9) AA (n = 432) AV + VV (n = 125 + 8)
Age (yr) 27.85 ± 4.33 28.15 ± 3.80 24.79 ± 3.95 24.39 ± 3.70
BMI (kg/m2) 20.98 ± 3.00 21.33 ± 2.53 23.21 ± 4.41 22.66 ± 3.62
Oxidative stress parameters
TOS (nmol H2O2 Equiv./mL) 11.06 ± 5.13 11.51 ± 5.81 14.95 ± 11.25 15.00 ± 9.43
T-AOC (U/ml/min) 14.58 ± 2.62 14.39 ± 2.86 15.82 ± 3.12 15.86 ± 2.92
OSI 0.78 ± 0.39 0.83 ± 0.44 1.00 ± 0.84 0.99 ± 0.65
MDA (nmol/ml) 3.64 ± 1.05 3.69 ± 1.15 4.38 ± 1.31 4.27 ± 1.31
PAF-AH activities and frequencies of PAF-AH G449T genotypea
Plasma PAF-AH (nmol/min/ml) 48.22 ± 10.85 48.68 ± 10.79 47.37 ± 13.78 47.70 ± 9.09
H-PAF-AH (nmol/min/ml) 5.17 ± 1.57 4.96 ± 1.21 4.67 ± 2.03 4.66 ± 1.40
ApoB-PAF-AH (nmol/min/ml) 43.04 ± 9.92 43.72 ± 10.12 42.70 ± 12.63 43.04 ± 8.53
ApoB-PAF-AH/H-PAF-AH 8.79 ± 2.52 9.13 ± 2.34 9.97 ± 3.07 10.31 ± 6.10
PAF-AH G449T, n (%)
GG 185 (92.0%) 70 (94.6%) 190 (85.2%) 53 (91.4%)
GT + TT 16 + 0 (8.0%) 4 + 0 (5.4%) 29 + 4 (14.8%) 5 + 0 (8.6%)
Values are presented as the mean ± SD
TOS total oxidant status, T-AOC total antioxidant capacity, OSI oxidative stress index, PAF-AH platelet activating factor acetylhydrolase, H-PAF-AH HDL-associated
PAF-AH, ApoB-PAF-AH apolipoprotein B-containing lipoprotein-associated PAF-AH
Comparisons of oxidative stress parameters and PAF-AH activities were corrected for differences in age and BMI between the two groups
aControls: AA (n = 201), AV + VV (n = 70 + 4); PCOS: AA (n = 223), AV + VV (n = 55 + 3)
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